1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Golden Throat Holdings Group Co Ltd

Golden Throat Holdings Group Co Ltd

HHKEX:6896
1.95
HKD
+0.04
(+1.83%)
2.40BMarket Cap
Golden Throat Holdings Group Co Ltd
HKEX:6896
(Hong Kong Exchange)

Recent

price

1.95

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.11
1.11
1.03
0.84
0.94
1.08
0.88
1.11
1.34
1.3
1.6
1.28
- -
Revenue per Share
0.22
0.24
0.14
0.08
0.14
0.23
0.21
0.25
0.38
0.34
0.43
0.34
- -
Basic EPS, GAAP
0.31
0.08
0.01
-0.01
0.09
0.12
0.11
0.15
0.35
0.3
0.55
0.11
- -
Free Cash Flow per Basic Share
0.28
0.22
0.05
0.11
0.1
0.11
0.1
0.05
0.15
0.33
0.55
0.46
- -
Dividend per Share
0.12
1.29
1.33
1.28
1.43
1.56
1.65
1.85
2.08
2.1
1.98
1.86
1.98
Book Value per Share
0.12
1.29
1.33
1.28
1.43
1.56
1.65
1.85
2.08
2.1
1.98
1.86
1.98
Tangible Book Value per Share
545
639
748
739
739
739
739
739
739
739
739
739
739
Basic Weighted Avg Shares
607
707
768
624
694
797
647
821
992
961
1,185
943
- -
Sales/Revenue/Turnover
28.61
28.86
23.44
13.55
24.69
28.33
23.78
27.23
37.08
36.35
36.21
33.54
- -
Operating Margin (%)
9
5
5
7
6
10
32
37
39
39
36
34
- -
Depreciation Expense
122
155
103
61
102
168
154
188
281
250
319
251
- -
Net Income, GAAP
22.4
23.62
41.29
34.84
31.63
23.78
18.87
20.77
25.21
30.71
27.13
23.61
- -
Effective Tax Rate (%)
20.09
21.87
13.4
9.84
14.72
21.03
23.81
22.87
28.35
26.02
26.89
26.63
- -
Profit Margin (%)
24
886
858
758
758
677
696
856
1,060
1,111
1,056
957
1,056
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
45
70
45
LT Debt
91
968
987
944
1,057
1,154
1,220
1,365
1,539
1,551
1,466
1,377
1,466
Total Equity
- -
23.66
9.44
4.92
10.09
13.38
10.69
11.52
15.29
12.19
15.65
12.09
- -
Return on Invested Capital (%)
- -
26.05
10.15
6.19
9.68
14.57
12.46
13.05
16.94
13.65
17.11
13.61
- -
Return on Capital (%)
- -
29.18
10.53
6.36
10.21
15.16
12.98
14.52
19.37
16.19
21.12
17.67
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
412
502
382
LT Borrowings
- -
10
45
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
739
739
739
Market Capitalization
2,251
2,099
2,251

Working Capital

CNY

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
1,818
1,590
1,756
Cash, Cash Equivalents & STI
1,072
1,040
1,141
Accounts Receivable, Net
56
42
32
Inventories
63
88
65
Total Current Liabilities
707
780
700
Payables & Accruals
- -
- -
- -
ST Debt
412
502
382
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.83%
2.76%
-6.11%
Free Cash Flow
-116.16%
31.08%
-80.91%
Net Income, GAAP
11.55%
13.37%
-21.16%
Sales/Revenue/Turnover
4.46%
9.5%
-20.4%
Total Cash Common Dividend
35.15%
63.94%
-16.12%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
961
2024
- -
- -
1,185
2025
- -
- -
943

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.34
2024
- -
- -
0.43
2025
- -
- -
0.34

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.33
2024
- -
- -
0.55
2025
- -
- -
0.46
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Golden Throat Holdings Group Company Limited operates as an investment holding company, engaged in the production and distribution of various pharmaceutical and health-oriented food items across the People's Republic of China and globally. The company’s flagship offering, Golden Throat Lozenges, is an established over-the-counter medication formulated to alleviate discomfort from sore and dry throats, and hoarseness associated with acute pharyngitis. Beyond its primary lozenge product, the group manufactures a series of Golden Throat lozenges, including Dule lozenges and sugar-free versions, which come in a variety of natural flavors like orange, fructus momordicae, chrysanthemum, American ginseng, and hawthorn. Additionally, its portfolio encompasses Yinxingye tablets, a prescription medication aimed at enhancing blood circulation and clearing energy pathways, as well as a range of herbal beverages, intestinal series products, and probiotic lozenges. While its main revenue streams originate from mainland China, Golden Throat Holdings exports its products to a broad international market spanning approximately 60 countries and regions, including the United States, Canada, Russia, European Union member states, Australia, Southeast Asia, the Middle East, Mexico, and Africa. Established in 1956, the company is headquartered in Liuzhou, People's Republic of China. The company recently announced a projected decrease in profit for the first half of 2025, driven by evolving industry conditions and strategic marketing adjustments.